Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high269.75 11/09/17
52 week low138.25 03/01/17
52 week change -17.50 (-9.46%)
4 week volume779,955 25/10/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Therapeutics plc : Miscellaneous

Summit to present at Duchenne Conference

Summit Therapeutics has confirmed that new preclinical data shows a positive effect of utrophin modulation on improvin...

Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action Duchenne

A statement giving an update on research (e.g. clinical trials)

Summit inks revenue sharing agreement with Wellcome Trust

Summit Therapeutics confirmed that the Company has entered into an equity and revenue sharing agreement with the W...

Summit Therapeutics Announces Revenue Sharing Agreement with Wellcome Trust

Statement regarding an alliance between entities

Summit Therapeutics plc : Grant of share options

Summit Therapeutics plc : Block listing application

Six monthly notification by a company issuing securities on aregular basisNotification of a company’s annual report & accounts

Summit Therapeutics plc : Holding(s) in Company

Notification of major interests in shares

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Dilution

    So after todays press release all of the gain made following the previous press release has been wiped out in one foul swoop. It seems every time we get a decent rise in the ...
    14-Sep-2017
    scep
  • Re: NEW ARTICLE: Four AIM shares for a p...

    ps valid points raised. Sold these in two lots, 247 and 177 as could only see drift until 2018. C diff drug trying to break into an established market, always difficult ...
    6-Jul-2017
    bobsson
  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...
    18-Jun-2017
    pharmaspecialist

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
LLOYDS GRP.22%
RANGE RES.21%
ROYAL BANK SCOT17%
SIRIUS MINERALS15%
ROCKHOPPER14%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account